12,372 trials
Contraception
Primary: The Change in Average of the 3 Highest Visual Analog Scale (VAS) Values of the Hormone Withdrawal-associated Symptoms Pelvic Pain or Headache During Cycle Days 22 to 28…
Paroxysmal Atrial Fibrillation
Primary: Acute Procedural Success (APS) — 160 participants
Face-lift · Facial Rhytidectomy
Primary: Total Volume of Drainage on Each Side of the Face — 20.0; 8.0 mL — p=<0.0001
Leukemia
Primary: 2-year Disease-free Survival (DFS) — 39; 50 Percentage of population — p=<0.001
Asthma
Primary: Morning Peak Expiratory Flow (AM PEF) — 25.40; 19.90 Liters/minutes
Asthma
Primary: Number of Patients With Adverse Events (AEs). — 118; 116 Participants
Hypertension
Primary: DBP and SBP Change From Baseline in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean — -12.76; -23.82 mmHg
Psoriasis
Primary: Psoriasis Area-and-severity Index (PASI) 75% Improvement From Baseline at Week 12. — 8; 171; 170 Participants — p=<0.001
Parkinson Disease
Primary: Adverse Effects Experienced — 29; 43 number of events
Pain · Multiple Sclerosis
Primary: Change From Baseline in Mean Pain Box Scale-11 Score at 3 Weeks. — -1.3; -0.9 units on a scale — p=0.332
Rheumatoid Arthritis
Primary: Number of Participants With an American College of Rheumatology (ACR) 50 Response at Week 14 — 28; 16; 27; 25 Participants — p=0.051
Carcinoma, Renal Cell
Primary: Number of Participants With Preference for Pazopanib Versus Sunitinib as Assessed by the Patient Preference Questionnaire (PPQ) — 19; 6; 37; 43 participants — p=<0.001
Dry Eye Syndromes · Keratoconjunctivitis Sicca
Primary: Change on Ocular Surface Disease Index (OSDI)
Primary Immunodeficiency Diseases (PID)
Primary: Ratio of Area Under the Concentration Curve (AUC 0-τ)/Week Following IV Administration to SC Administration of IGIV, 10% at an Adjusted/Individual Adapted Dose (Part…
Multiple Sclerosis · Spasticity · Pain
Primary: Incidence of Adverse Events as a Measure of Subject Safety. — 477 participants